LCWM
VRTX icon

Legacy Capital Wealth Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Legacy Capital Wealth Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.64M Buy
7,333
+1,484
+25% +$658K 1.67% 25
2026
Q1 		$2.61M Buy
5,849
+806
+16% +$376K 1.5% 35
2025
Q4 		$2.29M Buy
+5,043
New +$2.17M 1.38% 32
2024
Q4 		$1.19M Buy
+2,946
New +$1.37M 1.18% 31

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Legacy Capital Wealth Management's VRTX Position: Q2 2026 in Review

Legacy Capital Wealth Management increased its Vertex Pharmaceuticals (VRTX) stake by 25% in Q2 2026, buying an estimated $658K and bringing the position to 7,333 shares worth $3.64M. The position accounts for 1.67% of the portfolio, ranked #25.

Legacy Capital Wealth Management first reported a position in VRTX in Q4 2024 and has held it in 4 quarters since. 1,762 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Legacy Capital Wealth Management held 7,333 shares of Vertex Pharmaceuticals worth $3.64M as of Q2 2026.
  • Legacy Capital Wealth Management bought 1,484 Vertex Pharmaceuticals shares in Q2 2026, an estimated $658K.
  • Vertex Pharmaceuticals made up 1.67% of Legacy Capital Wealth Management's portfolio in Q2 2026, its #25 holding.
  • Legacy Capital Wealth Management first reported a position in Vertex Pharmaceuticals in Q4 2024 and has held it in 4 quarters since.
  • 1,762 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Legacy Capital Wealth Management's 13F filing for Q2 2026, filed 13 Aug 2026.